{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:04:41Z","timestamp":1790247881677,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS\u20102025\u201023963353"],"award-info":[{"award-number":["RS\u20102025\u201023963353"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016275","name":"Seoul National University Bundang Hospital","doi-asserted-by":"publisher","award":["02\u20102024\u20100027"],"award-info":[{"award-number":["02\u20102024\u20100027"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","award":["04\u20102025\u20100470"],"award-info":[{"award-number":["04\u20102025\u20100470"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To characterize the heterogeneity of pathological responses in the breast and regional lymph nodes after neoadjuvant pembrolizumab\u2010based chemoimmunotherapy in early\u2010stage triple\u2010negative breast cancer (TNBC) and to explore their clinical implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A total of 203 patients with TNBC treated with neoadjuvant chemotherapy combined with pembrolizumab followed by surgery were included. Histopathological features of baseline biopsy and post\u2010treatment specimens, including residual carcinoma patterns and tumour\u2010bed features, were systematically reviewed and correlated with treatment response and clinical outcomes. Pathological complete response (pCR) was achieved in 63.1% of patients. Higher histological grade, increased tumour\u2010infiltrating lymphocytes (TILs), and higher Ki\u201067 labelling index were independently associated with pCR. Residual carcinoma patterns and tumour\u2010bed changes were heterogeneous, with residual disease most commonly presenting as a solitary, confined focus (51.4%). Fibrotic tumour beds were more frequently observed in non\u2010pCR cases, whereas stromal elastosis was enriched among pCR cases. Nodal responses were also heterogeneous, including complete nodal response (23.6%), non\u2010response (8.4%), and mixed nodal response (7.4%). Disease recurrence was more frequent among patients without pCR, and among those with multifocal baseline tumours, higher cT stage, rare histological subtypes, low TILs and residual nodal disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real\u2010world study provides a comprehensive pathological characterization of breast and nodal responses after neoadjuvant chemoimmunotherapy in early TNBC, highlighting heterogeneity beyond pCR and ypN staging and offering a more detailed characterization of treatment\u2010response patterns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/his.70285","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:20:41Z","timestamp":1790245241000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab\u2010based chemoimmunotherapy in early triple\u2010negative breast cancer and its clinical significance"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7687-6477","authenticated-orcid":false,"given":"Jiwon","family":"Koh","sequence":"first","affiliation":[{"name":"Department of Pathology Seoul National University Hospital, Seoul National University College of Medicine  Seoul Republic of Korea"},{"name":"Cancer Research Institute Seoul National University  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-8738","authenticated-orcid":false,"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine Seoul National University Bundang Hospital, Seoul National University College of Medicine  Seongnam Gyeonggi Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1712-5585","authenticated-orcid":false,"given":"Hye Yeon","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine Seoul National University Hospital, Seoul National University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8822-7899","authenticated-orcid":false,"given":"Hyun Jung","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Pathology Seoul National University Bundang Hospital, Seoul National University College of Medicine  Seongnam Gyeonggi Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8791-5945","authenticated-orcid":false,"given":"Hyun\u2010Jung","family":"Sung","sequence":"additional","affiliation":[{"name":"Department of Pathology Seoul National University Bundang Hospital, Seoul National University College of Medicine  Seongnam Gyeonggi Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2508-9796","authenticated-orcid":false,"given":"Han Suk","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Pathology Seoul National University Hospital, Seoul National University College of Medicine  Seoul Republic of Korea"},{"name":"Cancer Research Institute Seoul National University  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6031-3629","authenticated-orcid":false,"given":"Jung Ho","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology Seoul National University Hospital, Seoul National University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-5080","authenticated-orcid":false,"given":"Jaemoon","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Pathology Seoul National University Hospital, Seoul National University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-3240","authenticated-orcid":false,"given":"Kyung\u2010Hun","family":"Lee","sequence":"additional","affiliation":[{"name":"Cancer Research Institute Seoul National University  Seoul Republic of Korea"},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine Seoul National University Hospital, Seoul National University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7133-6669","authenticated-orcid":false,"given":"Dae\u2010Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Cancer Research Institute Seoul National University  Seoul Republic of Korea"},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine Seoul National University Hospital, Seoul National University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7125-9795","authenticated-orcid":false,"given":"Changhee","family":"Park","sequence":"additional","affiliation":[{"name":"Cancer Research Institute Seoul National University  Seoul Republic of Korea"},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine Seoul National University Hospital, Seoul National University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-6273","authenticated-orcid":false,"given":"Jeongmin","family":"Seo","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine Seoul National University Bundang Hospital, Seoul National University College of Medicine  Seongnam Gyeonggi Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3547-3521","authenticated-orcid":false,"given":"Heejung","family":"Chae","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine Seoul National University Bundang Hospital, Seoul National University College of Medicine  Seongnam Gyeonggi Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9874-7772","authenticated-orcid":false,"given":"Woochan","family":"Hwang","sequence":"additional","affiliation":[{"name":"Lunit Inc.  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-3583","authenticated-orcid":false,"given":"Ye Yoon","family":"Suh","sequence":"additional","affiliation":[{"name":"Lunit Inc.  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0702-0608","authenticated-orcid":false,"given":"Chang Ho","family":"Ahn","sequence":"additional","affiliation":[{"name":"Lunit Inc.  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-6533","authenticated-orcid":false,"given":"Seock\u2010Ah","family":"Im","sequence":"additional","affiliation":[{"name":"Cancer Research Institute Seoul National University  Seoul Republic of Korea"},{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine Seoul National University Hospital, Seoul National University College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-3620","authenticated-orcid":false,"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine Seoul National University Bundang Hospital, Seoul National University College of Medicine  Seongnam Gyeonggi Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-7268","authenticated-orcid":false,"given":"So Yeon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pathology Seoul National University Bundang Hospital, Seoul National University College of Medicine  Seongnam Gyeonggi Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple\u2010negative breast cancer (KEYNOTE\u2010355): a randomised, placebo\u2010controlled, double\u2010blind, phase 3 clinical trial","volume":"396","author":"Cortes J","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple\u2010negative breast cancer","volume":"387","author":"Cortes J","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple\u2010negative breast cancer","volume":"382","author":"Schmid P","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event\u2010free survival with pembrolizumab in early triple\u2010negative breast cancer","volume":"386","author":"Schmid P","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early\u2010stage triple\u2010negative breast cancer","volume":"391","author":"Schmid P","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long\u2010term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar P","year":"2014","journal-title":"Lancet"},{"key":"e_1_2_11_8_1","article-title":"Clinicopathological evaluation of triple\u2010negative breast cancer treated with keynote\u2010522 regimen","volume":"30","author":"Khoury T","year":"2025","journal-title":"Oncologia"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1245\/s10434-025-17081-7","article-title":"Predictors of pathologic complete response with neoadjuvant chemo\u2010immunotherapy in early\u2010stage triple\u2010negative breast cancer","volume":"32","author":"Perry LM","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-023-07233-2","article-title":"High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE\u2010522 chemoimmunotherapy","volume":"205","author":"Wood SJ","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1245\/s10434-014-4054-2","article-title":"Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy","volume":"22","author":"Lee HJ","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41379-020-00714-5","article-title":"Clinico\u2010pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer","volume":"34","author":"Pastorello RG","year":"2021","journal-title":"Mod. Pathol."},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013College of American Pathologists Guideline update","volume":"41","author":"Wolff AC","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor\u2010infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado R","year":"2015","journal-title":"Ann. Oncol."},{"key":"e_1_2_11_15_1","article-title":"Assessment of Ki67 in breast cancer: Updated recommendations from the international Ki67 in breast cancer working group","volume":"113","author":"Nielsen TO","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","DOI":"10.1038\/srep30091","article-title":"Value of Ki\u201067 expression in triple\u2010negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin","volume":"6","author":"Wang R\u2010X","year":"2016","journal-title":"Sci. Rep."},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4132\/jptm.2020.11.20","article-title":"Standardized pathology report for breast cancer","volume":"55","author":"Cho SY","year":"2021","journal-title":"J. Pathol. Transl. Med."},{"key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans WF","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91643-z","article-title":"Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer","volume":"11","author":"Chung YR","year":"2021","journal-title":"Sci. Rep."},{"key":"e_1_2_11_20_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008339","article-title":"Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types","volume":"12","author":"Shen J","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1245\/s10434-024-16390-7","article-title":"Real\u2010world outcomes with the KEYNOTE\u2010522 regimen in early\u2010stage triple\u2010negative breast cancer","volume":"32","author":"Connors C","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"8854","DOI":"10.3390\/jcm14248854","article-title":"BRCA1 and 2 mutations and efficacy of pembrolizumab\u2010based neoadjuvant chemotherapy in triple\u2010negative breast cancer: A real\u2010world multicenter analysis","volume":"14","author":"Fedele P","year":"2025","journal-title":"J. Clin. Med."},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.3390\/cancers17213554","article-title":"Impact of chemotherapy dose intensity on pathological complete response in pembrolizumab\u2010treated early triple\u2010negative breast cancer: A real\u2010world multicenter analysis","volume":"17","author":"Fedele P","year":"2025","journal-title":"Cancer"},{"key":"e_1_2_11_24_1","first-page":"566","article-title":"Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple\u2010negative breast cancer: a real\u2010world analysis","volume":"29","author":"LeVee A","year":"2024","journal-title":"Oncologia"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-025-07758-8","article-title":"Adverse events in patients treated with neoadjuvant chemo\/immunotherapy for triple negative breast cancer: results from seven academic medical centers","volume":"213","author":"Mezzanotte\u2010Sharpe J","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_11_26_1","doi-asserted-by":"crossref","unstructured":"MugluH S\u00fcngerE \u00d6zkanOet\u00a0al.Neoadjuvant chemoimmunotherapy in early\u2010stage TNBC: real\u2010world predictors of pCR and survival: Turkish Oncology Group Study.2025https:\/\/doi.org\/10.2139\/ssrn.5463199.","DOI":"10.2139\/ssrn.5463199"},{"key":"e_1_2_11_27_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110011","article-title":"Real\u2010world evidence of the efficacy of neoadjuvant pembrolizumab in triple\u2010negative breast cancer: A surgeon's point of view","volume":"51","author":"Park WK","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"key":"e_1_2_11_28_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmorw.2024.100061","article-title":"Real\u2010world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple\u2010negative breast cancer","volume":"5","author":"Rached L","year":"2024","journal-title":"ESMO Real World Data Digit. Oncol."},{"key":"e_1_2_11_29_1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13058-024-01944-0","article-title":"Stromal tumor\u2010infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single\u2010center real\u2010world study","volume":"26","author":"Bae SJ","year":"2024","journal-title":"Breast Cancer Res."},{"key":"e_1_2_11_30_1","article-title":"Abstract LB1\u201007: exploratory biomarker analysis of the phase 3 KEYNOTE\u2010522 study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early\u2010stage TNBC","volume":"31","author":"O'Shaughnessy J","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-017-0011-0","article-title":"Dramatic response of metaplastic breast cancer to chemo\u2010immunotherapy","volume":"3","author":"Adams S","year":"2017","journal-title":"Npj Breast Cancer"},{"key":"e_1_2_11_32_1","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1159\/000534146","article-title":"Complete response of triple\u2010negative metaplastic carcinoma of the breast using pembrolizumab","volume":"16","author":"Ladwa A","year":"2023","journal-title":"Case Rep. Oncol."},{"key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41523-025-00816-w","article-title":"Predictors of response to neoadjuvant chemo\u2010immunotherapy in metaplastic triple\u2010negative breast cancer","volume":"11","author":"Abuhadra N","year":"2025","journal-title":"Npj. Breast Cancer"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1097\/JS9.0000000000001360","article-title":"Integrative analysis identifies molecular features of fibroblast and the significance of fibrosis on neoadjuvant chemotherapy response in breast cancer","volume":"110","author":"Wang X","year":"2024","journal-title":"Int. J. Surg. (Lond, Engl)"},{"key":"e_1_2_11_35_1","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","article-title":"Cancer\u2010associated fibroblasts suppress CD8+ T\u00a0cell infiltration and confer resistance to immune checkpoint blockade","volume":"82","author":"Jenkins L","year":"2022","journal-title":"Cancer Res."},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4048\/jbc.2023.0264","article-title":"Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in human epidermal growth factor 2\u2010positive\/triple\u2010negative breast cancer patients with excellent response","volume":"27","author":"Ryu JM","year":"2024","journal-title":"J. Breast Cancer"}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.70285","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/his.70285","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.70285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:20:47Z","timestamp":1790245247000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/his.70285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":35,"alternative-id":["10.1111\/his.70285"],"URL":"https:\/\/doi.org\/10.1111\/his.70285","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"2026-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"his.70285"}}